Gut Microbes
(Dec 2024)
Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease
Femke M. Prins,
Iwan J. Hidding,
Marjolein A.Y. Klaassen,
Valerie Collij,
Johannes P.D. Schultheiss,
Werna T.C. Uniken Venema,
Amber Bangma,
Jurne B. Aardema,
Bernadien H. Jansen,
Wout G.N. Mares,
Ben J.M. Witteman,
Eleonora A.M. Festen,
Gerard Dijkstra,
Marijn C. Visschedijk,
Herma H. Fidder,
Arnau Vich Vila,
Bas Oldenburg,
Ranko Gacesa,
Rinse K. Weersma
Affiliations
Femke M. Prins
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Iwan J. Hidding
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Marjolein A.Y. Klaassen
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Valerie Collij
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Johannes P.D. Schultheiss
Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
Werna T.C. Uniken Venema
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Amber Bangma
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Jurne B. Aardema
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Bernadien H. Jansen
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Wout G.N. Mares
Gastroenterology and Hepatology Department, Hospital Gelderse Vallei, Ede, The Netherlands
Ben J.M. Witteman
Gastroenterology and Hepatology Department, Hospital Gelderse Vallei, Ede, The Netherlands
Eleonora A.M. Festen
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Gerard Dijkstra
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Marijn C. Visschedijk
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Herma H. Fidder
Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
Arnau Vich Vila
Department of Microbiology and Immunology, Rega Institute for Medical Research, Leuven, Belgium
Bas Oldenburg
Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
Ranko Gacesa
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Rinse K. Weersma
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
DOI
https://doi.org/10.1080/19490976.2024.2391505
Journal volume & issue
Vol. 16,
no. 1
Abstract
Read online
Emerging evidence suggests the gut microbiome’s potential in predicting response to biologic treatments in patients with inflammatory bowel disease (IBD). In this prospective study, we aimed to predict treatment response to vedolizumab and ustekinumab, integrating clinical data, gut microbiome profiles based on metagenomic sequencing, and untargeted fecal metabolomics. We aimed to identify predictive biomarkers and attempted to replicate microbiome-based signals from previous studies. We found that the predictive utility of the gut microbiome and fecal metabolites for treatment response was marginal compared to clinical features alone. Testing our identified microbial ratios in an external cohort reinforced the lack of predictive power of the microbiome. Additionally, we could not confirm previously published predictive signals observed in similar sized cohorts. Overall, these findings highlight the importance of external validation and larger sample sizes, to better understand the microbiome’s impact on therapy outcomes in the setting of biologicals in IBD before potential clinical implementation.
Keywords
Published in Gut Microbes
ISSN
1949-0976 (Print)
1949-0984 (Online)
Publisher
Taylor & Francis Group
Country of publisher
United States
LCC subjects
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
Website
https://www.tandfonline.com/journals/kgmi
About the journal
WeChat QR code
Close